BRPI0417958A - composto, composição farmacêutica, processo para a preparação de um sal maleato, uso de um sal maleato, e, método para produzir um efeito redutor na permeabilidade antiangiogênica e/ou vascular em um animal de sangue quente - Google Patents
composto, composição farmacêutica, processo para a preparação de um sal maleato, uso de um sal maleato, e, método para produzir um efeito redutor na permeabilidade antiangiogênica e/ou vascular em um animal de sangue quenteInfo
- Publication number
- BRPI0417958A BRPI0417958A BRPI0417958-7A BRPI0417958A BRPI0417958A BR PI0417958 A BRPI0417958 A BR PI0417958A BR PI0417958 A BRPI0417958 A BR PI0417958A BR PI0417958 A BRPI0417958 A BR PI0417958A
- Authority
- BR
- Brazil
- Prior art keywords
- maleate salt
- vascular permeability
- antiangiogenic
- warm
- compound
- Prior art date
Links
- 150000002688 maleic acid derivatives Chemical class 0.000 title abstract 4
- 230000008728 vascular permeability Effects 0.000 title abstract 4
- 241001465754 Metazoa Species 0.000 title abstract 3
- 238000004519 manufacturing process Methods 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 230000001603 reducing effect Effects 0.000 title abstract 3
- 230000001772 anti-angiogenic effect Effects 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 4
- JRMGHBVACUJCRP-BTJKTKAUSA-N (z)-but-2-enedioic acid;4-[(4-fluoro-2-methyl-1h-indol-5-yl)oxy]-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline Chemical class OC(=O)\C=C/C(O)=O.COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCCN1CCCC1 JRMGHBVACUJCRP-BTJKTKAUSA-N 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/145—Maleic acid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Reproductive Health (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
"COMPOSTO, COMPOSIçãO FARMACêUTICA, PROCESSO PARA A PREPARAçãO DE UM SAL MALEATO, USO DE UM SAL MALEATO, E, MéTODO PARA PRODUZIR UM EFEITO REDUTOR NA PERMEABILIDADE ANTIANGIOGêNICA E/OU VASCULAR EM UM ANIMAL DE SANGUE QUENTE". A presente invenção diz respeito a sal maleato AZD2171, a formas cristalinas particulares do sal maleato AZD2171, a processos par sua preparação, a composições farmacêuticas contendo-os como ingrediente ativo, a seu uso na fabricação de medicamentos para uso na produção dos efeitos de redução da permeabilidade antiangiogênica e/ou vascular em animais de sangue quente, tais como seres humanos, e a seu uso em método para o tratamento de estados de doença associados com a angiogênese e/ou a permeabilidade vascular aumentada.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0330002.7A GB0330002D0 (en) | 2003-12-24 | 2003-12-24 | Quinazoline derivatives |
| PCT/GB2004/005359 WO2005061488A1 (en) | 2003-12-24 | 2004-12-18 | Maleate salts of a quinazoline derivative useful as an antiangiogenic agent |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0417958A true BRPI0417958A (pt) | 2007-03-27 |
| BRPI0417958B1 BRPI0417958B1 (pt) | 2019-02-05 |
| BRPI0417958B8 BRPI0417958B8 (pt) | 2021-05-25 |
Family
ID=30776508
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0417958A BRPI0417958B8 (pt) | 2003-12-24 | 2004-12-18 | sais cristalinos de maleato de [4-((4-fluoro-2-metil-1h-indol-5-il)-6-metóxi-7-(3-(pirrolidin-1-il) propóxi) quinazolina], composição farmacêutica, processo e uso dos ditos sais cristalinos |
Country Status (32)
| Country | Link |
|---|---|
| US (6) | US20070129387A1 (pt) |
| EP (1) | EP1699782B1 (pt) |
| JP (2) | JP5009628B2 (pt) |
| KR (1) | KR101240872B1 (pt) |
| CN (2) | CN1898232B (pt) |
| AR (2) | AR046993A1 (pt) |
| AT (1) | ATE471936T1 (pt) |
| AU (1) | AU2004303590B2 (pt) |
| BR (1) | BRPI0417958B8 (pt) |
| CA (1) | CA2548662C (pt) |
| CY (1) | CY1110730T1 (pt) |
| DE (1) | DE602004027833D1 (pt) |
| DK (1) | DK1699782T3 (pt) |
| ES (1) | ES2345776T3 (pt) |
| GB (1) | GB0330002D0 (pt) |
| HR (1) | HRP20100455T1 (pt) |
| IL (1) | IL176308A (pt) |
| MX (1) | MXPA06007191A (pt) |
| MY (1) | MY145143A (pt) |
| NO (1) | NO336613B1 (pt) |
| NZ (1) | NZ547547A (pt) |
| PL (1) | PL1699782T3 (pt) |
| PT (1) | PT1699782E (pt) |
| RS (1) | RS51387B (pt) |
| RU (1) | RU2425043C2 (pt) |
| SA (1) | SA05250464B1 (pt) |
| SI (1) | SI1699782T1 (pt) |
| TW (1) | TWI339119B (pt) |
| UA (1) | UA91332C2 (pt) |
| UY (1) | UY28702A1 (pt) |
| WO (1) | WO2005061488A1 (pt) |
| ZA (1) | ZA200605225B (pt) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1154774E (pt) | 1999-02-10 | 2005-10-31 | Astrazeneca Ab | Derivados de quinazolina como inibidores de angiogenese |
| SI1474420T1 (sl) * | 2002-02-01 | 2012-06-29 | Astrazeneca Ab | Spojine kinazolina |
| GB0330002D0 (en) * | 2003-12-24 | 2004-01-28 | Astrazeneca Ab | Quinazoline derivatives |
| MXPA06010755A (es) * | 2004-03-23 | 2006-12-15 | Astrazeneca Ab | Terapia de combinacion. |
| GB0523810D0 (en) * | 2005-11-23 | 2006-01-04 | Astrazeneca Ab | Pharmaceutical compositions |
| HRP20110365T1 (hr) * | 2005-12-22 | 2011-06-30 | Astrazeneca Ab | Kombinacija azd2171 i pemetrekseda |
| CL2007003158A1 (es) | 2006-11-02 | 2008-05-16 | Astrazeneca Ab | Procedimiento de preparacion de compuestos derivados de quinazolina o sus sales farmaceuticamente aceptables; compuestos intermediarios; procedimiento de preparacion. |
| CL2008000070A1 (es) * | 2007-01-17 | 2008-07-25 | Lg Life Sciences Ltd | Monosal del acido maleico (3-[({1-[(2-amino-9h-purin-9-il)metil]ciclopropil}oxi)metil]-8,8-dimetil-3,7-dioxo-2,4,6-trioxa-3 lambda 5-fosfanon-1-il-pivalato; composicion farmaceutica que comprende a dicha monosal; y uso para el tratamiento del virus h |
| EP2706358A3 (en) * | 2008-12-23 | 2014-05-07 | Merck Patent GmbH | Biomarkers for inhibitors with anti-angiogenic activity |
| WO2011036895A1 (ja) * | 2009-09-25 | 2011-03-31 | 杏林製薬株式会社 | マレイン酸塩およびその結晶 |
| US20150165028A1 (en) * | 2012-06-25 | 2015-06-18 | Bayer Healthcare Llc | Topical ophthalmological pharmaceutical composition containing cediranib |
| US9007866B2 (en) | 2013-04-23 | 2015-04-14 | Tessera Inc. | Retention optimized memory device using predictive data inversion |
| US9458169B2 (en) | 2013-11-01 | 2016-10-04 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| CA3109285A1 (en) * | 2013-11-01 | 2015-05-07 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| CN105461698A (zh) * | 2014-09-12 | 2016-04-06 | 杭州普晒医药科技有限公司 | 西地尼布盐及其晶型、以及其制备方法和药物组合物 |
| WO2017035170A1 (en) * | 2015-08-24 | 2017-03-02 | Pliva Hrvatska D.O.O | Solid state forms of cediranib maleate |
| US20210322415A1 (en) | 2016-02-15 | 2021-10-21 | Astrazeneca Ab | Methods comprising fixed intermittent dosing of cediranib |
| US10336767B2 (en) | 2016-09-08 | 2019-07-02 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| EP3509423A4 (en) | 2016-09-08 | 2020-05-13 | Kala Pharmaceuticals, Inc. | CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF |
| AU2017324713B2 (en) | 2016-09-08 | 2020-08-13 | KALA BIO, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| US10255725B2 (en) * | 2016-11-16 | 2019-04-09 | Disney Enterprises, Inc. | Augmented reality interactive experience |
| CN110817898B (zh) * | 2018-08-13 | 2021-09-03 | 中国科学院大连化学物理研究所 | 一种具有ats骨架结构的磷酸硅铝分子筛及其制备方法和应用 |
| WO2024003241A1 (en) | 2022-06-30 | 2024-01-04 | Astrazeneca Ab | Treatment for immuno-oncology resistant subjects with an anti pd-l1 antibody an antisense targeted to stat3 and an inhibitor of ctla-4 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL81307A0 (en) | 1986-01-23 | 1987-08-31 | Union Carbide Agricult | Method for reducing moisture loss from plants and increasing crop yield utilizing nitrogen containing heterocyclic compounds and some novel polysubstituted pyridine derivatives |
| IL89029A (en) | 1988-01-29 | 1993-01-31 | Lilly Co Eli | Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them |
| US5411963A (en) | 1988-01-29 | 1995-05-02 | Dowelanco | Quinazoline derivatives |
| SG64322A1 (en) | 1991-05-10 | 1999-04-27 | Rhone Poulenc Rorer Int | Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase |
| US5710158A (en) | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| US5721237A (en) | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
| US5480883A (en) | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| US5714493A (en) | 1991-05-10 | 1998-02-03 | Rhone-Poulenc Rorer Pharmaceuticals, Inc. | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase |
| US6645969B1 (en) | 1991-05-10 | 2003-11-11 | Aventis Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase |
| CA2091204C (en) | 1992-03-11 | 1997-04-08 | Ronald J. Mattson | Antiischemic-piperazinyl and piperidinyl-cyclohexanes |
| GB9323290D0 (en) | 1992-12-10 | 1994-01-05 | Zeneca Ltd | Quinazoline derivatives |
| US5700823A (en) | 1994-01-07 | 1997-12-23 | Sugen, Inc. | Treatment of platelet derived growth factor related disorders such as cancers |
| RU2137762C1 (ru) | 1994-02-23 | 1999-09-20 | Пфайзер Инк. | 4-гетероциклил-замещенные производные хиназолина, фармацевтическая композиция |
| WO1995024190A2 (en) | 1994-03-07 | 1995-09-14 | Sugen, Inc. | Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof |
| DE4436509A1 (de) | 1994-10-13 | 1996-04-18 | Hoechst Schering Agrevo Gmbh | Substituierte Spiroalkylamino- und alkoxy-Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel und Fungizide |
| GB9505651D0 (en) | 1995-03-21 | 1995-05-10 | Agrevo Uk Ltd | AgrEvo UK Limited |
| US6046206A (en) | 1995-06-07 | 2000-04-04 | Cell Pathways, Inc. | Method of treating a patient having a precancerous lesions with amide quinazoline derivatives |
| GB9514265D0 (en) | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
| EP0860433B1 (en) | 1995-11-07 | 2002-07-03 | Kirin Beer Kabushiki Kaisha | Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| DE19614718A1 (de) | 1996-04-15 | 1997-10-16 | Hoechst Schering Agrevo Gmbh | Substituierte Pyridine/Pyrimidine, Verfahren zu ihrer Herstellung, und ihre Verwendung als Schädlingsbekämpfungsmittel |
| GB9707800D0 (en) | 1996-05-06 | 1997-06-04 | Zeneca Ltd | Chemical compounds |
| AR007857A1 (es) | 1996-07-13 | 1999-11-24 | Glaxo Group Ltd | Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen. |
| US6225318B1 (en) | 1996-10-17 | 2001-05-01 | Pfizer Inc | 4-aminoquinazolone derivatives |
| EP0837063A1 (en) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
| JP2002501532A (ja) | 1997-05-30 | 2002-01-15 | メルク エンド カンパニー インコーポレーテッド | 新規血管形成阻害薬 |
| ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
| ES2289791T3 (es) | 1997-08-22 | 2008-02-01 | Astrazeneca Ab | Derivados de oxindolilquinazolina como inhibidores de la angiogenesis. |
| US6162804A (en) | 1997-09-26 | 2000-12-19 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| GB9721437D0 (en) | 1997-10-10 | 1997-12-10 | Glaxo Group Ltd | Heteroaromatic compounds and their use in medicine |
| RS49779B (sr) | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze |
| GB9800575D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| US6172071B1 (en) | 1998-07-30 | 2001-01-09 | Hughes Institute | Lipid-lowering quinazoline derivative |
| US6184226B1 (en) | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
| GB2345486A (en) | 1999-01-11 | 2000-07-12 | Glaxo Group Ltd | Heteroaromatic protein tyrosine kinase inhibitors |
| UA71945C2 (en) | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
| JP3270834B2 (ja) | 1999-01-27 | 2002-04-02 | ファイザー・プロダクツ・インク | 抗がん剤として有用なヘテロ芳香族二環式誘導体 |
| PT1154774E (pt) * | 1999-02-10 | 2005-10-31 | Astrazeneca Ab | Derivados de quinazolina como inibidores de angiogenese |
| DE19911509A1 (de) | 1999-03-15 | 2000-09-21 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| TWI262914B (en) | 1999-07-02 | 2006-10-01 | Agouron Pharma | Compounds and pharmaceutical compositions for inhibiting protein kinases |
| PE20010306A1 (es) | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
| CA2387351C (en) | 1999-10-19 | 2009-09-08 | Merck & Co., Inc. | Indole derivatives as tyrosine kinase inhibitors |
| KR100881105B1 (ko) * | 1999-11-05 | 2009-02-02 | 아스트라제네카 아베 | Ｖｅｇｆ 억제제로서의 퀴나졸린 유도체 |
| GB0008269D0 (en) * | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
| US20030119060A1 (en) * | 2001-08-10 | 2003-06-26 | Desrosiers Peter J. | Apparatuses and methods for creating and testing pre-formulations and systems for same |
| SI1474420T1 (sl) | 2002-02-01 | 2012-06-29 | Astrazeneca Ab | Spojine kinazolina |
| GB0330002D0 (en) * | 2003-12-24 | 2004-01-28 | Astrazeneca Ab | Quinazoline derivatives |
| GB0406446D0 (en) * | 2004-03-23 | 2004-04-28 | Astrazeneca Ab | Combination therapy |
| GB0523810D0 (en) * | 2005-11-23 | 2006-01-04 | Astrazeneca Ab | Pharmaceutical compositions |
-
2003
- 2003-12-24 GB GBGB0330002.7A patent/GB0330002D0/en not_active Ceased
-
2004
- 2004-12-18 NZ NZ547547A patent/NZ547547A/xx not_active IP Right Cessation
- 2004-12-18 JP JP2006546311A patent/JP5009628B2/ja not_active Expired - Lifetime
- 2004-12-18 RS RSP-2010/0374A patent/RS51387B/sr unknown
- 2004-12-18 US US10/581,279 patent/US20070129387A1/en not_active Abandoned
- 2004-12-18 AT AT04806159T patent/ATE471936T1/de active
- 2004-12-18 SI SI200431472T patent/SI1699782T1/sl unknown
- 2004-12-18 BR BRPI0417958A patent/BRPI0417958B8/pt active IP Right Grant
- 2004-12-18 CA CA2548662A patent/CA2548662C/en not_active Expired - Lifetime
- 2004-12-18 CN CN2004800386656A patent/CN1898232B/zh not_active Expired - Lifetime
- 2004-12-18 EP EP04806159A patent/EP1699782B1/en not_active Expired - Lifetime
- 2004-12-18 RU RU2006126782/04A patent/RU2425043C2/ru active
- 2004-12-18 KR KR1020067014753A patent/KR101240872B1/ko not_active Expired - Lifetime
- 2004-12-18 PT PT04806159T patent/PT1699782E/pt unknown
- 2004-12-18 UA UAA200608165A patent/UA91332C2/uk unknown
- 2004-12-18 MX MXPA06007191A patent/MXPA06007191A/es active IP Right Grant
- 2004-12-18 PL PL04806159T patent/PL1699782T3/pl unknown
- 2004-12-18 CN CN2011100351254A patent/CN102153543B/zh not_active Expired - Lifetime
- 2004-12-18 WO PCT/GB2004/005359 patent/WO2005061488A1/en not_active Ceased
- 2004-12-18 DE DE602004027833T patent/DE602004027833D1/de not_active Expired - Lifetime
- 2004-12-18 AU AU2004303590A patent/AU2004303590B2/en not_active Expired
- 2004-12-18 HR HR20100455T patent/HRP20100455T1/hr unknown
- 2004-12-18 ES ES04806159T patent/ES2345776T3/es not_active Expired - Lifetime
- 2004-12-18 DK DK04806159.2T patent/DK1699782T3/da active
- 2004-12-22 MY MYPI20045318A patent/MY145143A/en unknown
- 2004-12-22 AR ARP040104882A patent/AR046993A1/es not_active Application Discontinuation
- 2004-12-23 UY UY28702A patent/UY28702A1/es not_active Application Discontinuation
- 2004-12-24 TW TW093140588A patent/TWI339119B/zh not_active IP Right Cessation
-
2005
- 2005-01-29 SA SA5250464A patent/SA05250464B1/ar unknown
-
2006
- 2006-06-12 NO NO20062703A patent/NO336613B1/no unknown
- 2006-06-14 IL IL176308A patent/IL176308A/en active IP Right Grant
- 2006-06-23 ZA ZA200605225A patent/ZA200605225B/en unknown
-
2009
- 2009-12-23 US US12/646,153 patent/US8859570B2/en active Active
-
2010
- 2010-08-09 CY CY20101100738T patent/CY1110730T1/el unknown
-
2011
- 2011-02-03 JP JP2011021384A patent/JP2011088936A/ja active Pending
-
2014
- 2014-09-18 US US14/489,721 patent/US9556151B2/en not_active Expired - Lifetime
-
2016
- 2016-06-10 AR ARP160101750A patent/AR104979A2/es not_active Application Discontinuation
- 2016-09-13 US US15/264,527 patent/US9890140B2/en not_active Expired - Fee Related
-
2017
- 2017-12-28 US US15/857,366 patent/US20180170913A1/en not_active Abandoned
-
2019
- 2019-01-04 US US16/240,587 patent/US20190375730A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0417958A (pt) | composto, composição farmacêutica, processo para a preparação de um sal maleato, uso de um sal maleato, e, método para produzir um efeito redutor na permeabilidade antiangiogênica e/ou vascular em um animal de sangue quente | |
| BRPI0611747A2 (pt) | composto ou um sal farmaceuticamente aceitÁvel do mesmo ou n-àxidos do mesmo, composiÇço farmacÊutica, mÉtodos para tratar uma infecÇço bacteriana e para inibir o dna girase bacteriana em um animal de sangue quente, uso de um composto ou um sal farmaceuticamente aceitÁvel do mesmo, e, processo para fabricar um composto ou um sal farmaceuticamente aceitÁvel do mesmo | |
| BR0009043A (pt) | Composto, composição farmacêutica, e, método de tratar uma doença em um animal em que a atividade da cisteìna protease contribui para a patologia e/ou sintomatologia da doença | |
| BR0209658A (pt) | Derivados de 4-amino-5-fenil-7-1ciclobutil-pirrolo [2,3-d] pirimidina | |
| BRPI0507755A (pt) | composto de pirazolina substituìda, processo para a sua manufatura, medicamentos e seus usos | |
| BR9810146A (pt) | Composto, processo para preparação do mesmo, composição farmacêutica e método para tratar ou prevenir doenças mediadas pela taquicinina | |
| BRPI0410477A (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, método para a profilaxia ou tratamento de uma condição quiral em um mamìfero, formulação farmacêutica, combinação, uso de um composto, e, processo para preparar um composto | |
| ES2087916T3 (es) | Derivado de pirimidina biciclico, metodo para producir el mismo, y preparacion farmaceutica que contiene el mismo como ingrediente activo. | |
| BR0214757A (pt) | Formulações farmacêuticas de derivados de platina | |
| BRPI0414330A (pt) | composto, processo para preparação do mesmo, métodos para produção de um efeito antibacteriano, para inibição de dna girase bacteriana, e para tratamento de uma infecção bacteriana em um animal de sangue quente, uso de um composto, e, composição farmacêutica | |
| BR0316397A (pt) | Tiouréias aril substituìdas e compostos relacionados como inibidores de replicação viral | |
| BRPI0013010B8 (pt) | formulação aquosa de cloreto de sódio de moxifloxacina, processo para sua preparação e aplicação da referida formulação, bem como preparado de combinação e aplicação de uma solução aquosa de cloridrato de moxifloxacina | |
| BRPI0415050A (pt) | composto, formulação farmacêutica, método para tratar ou reduzir risco de uma doença ou condição humanas, uso de um composto ou de um sal deste farmaceuticamente aceitável, e, processo para a preparação de um composto ou de um sal deste farmaceuticamente aceitável | |
| BRPI0606930A2 (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, processo para preparar um composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo, e, métodos para a produção de um efeito de inibição de b-raf em um animal de sangue quente, para a produção de um efeito anti-cáncer em um animal de sangue quente e para o tratamento de doenças de um animal em um animal de sangue quente | |
| BR0309083A (pt) | Compostos derivados de benzoxazinona, sua preparação e uso como medicamentos | |
| BR0316157A (pt) | Derivados de 4-amino-5-fenil-7-ciclohexil-pirrolo[2,3-d]pirimidina | |
| BRPI0507790A (pt) | composto de pirazolina substituìda, processo para a sua manufatura, medicamentos e seus usos | |
| DE69932939D1 (de) | Fulvinsäure und dessen verwendung zur behandlung von diversen krankheitszuständen | |
| BRPI0411503A (pt) | composto, composição farmacêutica, uso de um composto, método de tratar um ser humano que sofre de uma doença hiperproliferativa tal como cáncer, e, processo para a preparação de um composto | |
| BR0016430A (pt) | Método para o tratamento e/ou prevenção da tosse em um animal de sangue quente, uso de um composto, composto, e, composição farmacêutica | |
| EP1254658A4 (en) | MEDICINES | |
| BRPI0413413A (pt) | feniloxazolidinonas de piperidino substituìdo tendo atividade antimicrobiana com eficácia in vivo melhorada | |
| ATE289805T1 (de) | Verwendung von antiseptika zur herstelllung von arzneimitteln zur prophylaxe und behandlung von infektionen und/ oder funktionellen gewebeumformungen im körperinneren | |
| BR0116302A (pt) | Formas cristalinas de sais 2,3-dihidroxibutanodioato de 6-[(4-clorofenil)-hidróxi-(3-metil-3h-imidazol-4-il)-meti l]-4-(3-etinil-fenil)-1-metil-1h-quinolin-2-ona e método de produção | |
| BR0116653A (pt) | Medicamento contendo uma poliamina como substância ativa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 05/02/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 05/02/2019, OBSERVADAS AS CONDICOES LEGAIS |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/12/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B22O | Other matters related to patents and certificates of addition of invention: legal action concerning patent |
Free format text: INPI NO 52402.000177/2023-81 ORIGEM: PI0417958-7 PROCESSO NO: 1031616-24.2022.4.01.3400 ACAO PELO PROCEDIMENTO COMUM AUTOR: ASTRAZENECA AB REU(S): INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL ? INPI |
|
| B19A | Notification of judicial decision: notification of judicial decision |
Free format text: PROCESSO INPI: 52402.000177/2023-81 ACAO JUDICIAL: 1031616-24.2022.4.01.3400 - 7A VARA FEDERAL CIVEL DA SJDF NUP PRINCIPAL: 00424.254192/2022-1 NUP REMISSIVO: 00848.000013/2023-11 AUTOR: ASTRAZENECA AB REU: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL ? INPI DECISAO: "PUBLIQUE NA REVISTA DE PROPRIEDADE INDUSTRIAL QUE O PRAZO DE VIGENCIA DA PATENTE PI0417958-7 ESTA SOB DISCUSSAO JUDICIAL (?SUB JUDICE?), DEVENDO TAL INFORMACAO CONSTAR NO STATUS (PAGINA DE ANDAMENTO PROCESSUAL) DISPONIBILIZADO NO WEBSITEWWW.INPI.GOV.BR DA REFERIDA PATENTE, PARA FINS DE CONHECIMENTO POR PARTE DE TERCEIROS (ARTIGOS 59,INCISO II, 60 E 226 DA LEI DA PROPRIEDADE INDUSTRIAL)." |
|
| B19A | Notification of judicial decision: notification of judicial decision |
Free format text: PROCESSO INPI NO 52402.000177/2023-81 SENTENCA DE IMPROCEDENCIA: ACAO PELO PROCEDIMENTO COMUM CONTRA O INSTITUTO NACIONAL DE PROPRIEDADE INDUSTRIAL ? INPI PARA QUE SEJA RECONHECIDA A MORA ADMINISTRATIVA DA AUTARQUIA NO EXAME DA PATENTE PI0417958-7 E O AJUSTE DE SEU PRAZO DE VIGENCIA EM CORRESPONDENCIA AO NUMERO DE DIAS DE ATRASO. ANTE O EXPOSTO, JULGO IMPROCEDENTES OS PEDIDOS INICIAIS E EXTINGO O PROCESSO, COM RESOLUCAO DO MERITO, NOS TERMOS DO ART. 487, I, DO CPC. |